RESOURCES
Zen Health Blogs
Product updates and industry insights on defensible pharmacovigilance review and ICH M11 clinical trial protocol intelligence.
Product updates and industry insights on defensible pharmacovigilance review and ICH M11 clinical trial protocol intelligence.
Every adverse event report that lands on a safety desk carries a simple promise: someone, somewhere, needs this information to be accurate. Yet across the pharmacovigilance industry, ICSR quality remains one of the most persistent and least talked-about problems. Teams meet their reporting deadlines, but the cases they submit are often thin on detail, inconsistent in their clinical logic, or missing pieces that a medical reviewer needs to make a sound judgment.
This is not a small issue buried in back-office paperwork. Case quality decides whether a real safety signal gets caught early or gets lost in noise. A 2025 review of Eudravigilance reports on five commonly used drugs found that the average case scored just 11.57 out of a possible 25 on a structured quality framework, a result the study's authors called generally low across the board. That single number captures why so many pharmacovigilance teams feel like they are constantly playing catch-up.
This article looks at why ICSR quality remains such a stubborn challenge, what it actually costs a pharmacovigilance department, and where artificial intelligence can genuinely help without replacing the medical judgment that regulators expect to see.
Individual Case Safety Reports are supposed to be straightforward: someone reports an adverse event, a case processor captures it, and a medical reviewer assesses it.
In practice, the raw material safety teams work with messy things. Reports arrive from patients, doctors, nurses, call centers, and literature searches, each with a different level of detail and a different sense of what matters. That variability is the root of most ICSR quality problems.
Missing data is the most common complaint from case processors and medical reviewers alike. A report might name the drug but skip the dose. It might describe an adverse event but leave out the onset date. Research comparing reports from patients and citizens against those from healthcare professionals found that roughly one in three ICSRs from non-professional reporters had incomplete codification, a much higher rate than reports coming from clinicians. This gap matters because patient-generated reports now make up a growing share of total case volume, especially with the rise of direct-to-consumer drug advertising and social media reporting.
The Four Essential Elements of a Valid Case
Regulators do not expect every ICSR to be perfect, but they do expect four minimum elements before a case can be treated as valid for reporting purposes. The World Health Organization and the International Council for Harmonisation both define these as:
If even one of these four elements is missing, the case is technically non-valid and should trigger a follow-up request rather than a submission.
In real-world practice, this rule sounds simple but is hard to enforce consistently across thousands of cases a month, especially when reporters are vague about who they are or what exactly happened.
Inconsistent Clinical Information
Beyond missing fields, the bigger issue is often internal inconsistency. A narrative might describe a patient recovering, while the outcome field says the event was ongoing. A case might list a drug as "suspect" in one section and "concomitant" in another.
A study found that 34.9% of cases contained coding errors, including instances where drug abuse was mislabeled as overdose in 8% of cases. Errors like this do not just look sloppy. They actively distort how a drug's safety profile appears in aggregate data, which can throw off signal detection at the population level.
Manual Quality Checks Across Large Case Volumes
Even when a pharmacovigilance team has strong training and clear SOPs, the sheer volume of cases makes manual quality control difficult to sustain. Global case volumes have been climbing for years, driven by expanding drug portfolios, growing markets, and easier digital reporting channels.
Every case is still expected to pass through a quality review step before medical assessment, a process that typically relies on a reviewer manually checking data entry against the source document, line by line. When volumes spike, this manual bottleneck is usually the first place things start to slip.
Poor ICSR quality shows up as a single dramatic failure. It shows up as friction: a case that takes longer than it should, a reviewer who has to chase down information twice, and an audit finding that could have been avoided. These costs are easy to underestimate because they are spread across many small delays rather than one big event.
Every incomplete or inconsistent case usually means a follow-up request to the original reporter, and follow-up is slow by nature. A reporter may not respond for days or weeks, and in the meantime the case sits in a queue, pushing against regulatory deadlines.
Industry estimates suggest a typical case can take 15 days or more to move from intake to submission when manual, quality-driven bottlenecks are involved, compared to under 5 days when better structured workflows are in place. That gap has real consequences for teams working against 15-day expedited reporting timelines for serious, unexpected adverse events.
Medical reviewers are the most expensive and most specialized resource in a pharmacovigilance operation, and low-quality cases waste their time disproportionately. Instead of applying clinical judgement to assess casuality and seriousness, reviewers end up doing detective work: cross-checking narratives against structured fields, flagging contradictions, and sending cases back for correction. One industry analysis estimated that a mid-size company processing around 15,000 ICSRs a year could cut average processing time from four hours to 1.5 hours per case by addressing quality bottlenecks earlier in the workflow, saving tens of thousands of person-hours annually. Whatever the exact numbers at a given company, the pattern is consistent: rework compounds, and it falls hardest on the people whose time is hardest to replace.
The most serious consequence of poor ICSR quality is regulatory exposure. Health authorities do not just check whether a case was submitted on time; they check whether the underlying data was complete, accurate, and properly assessed. Recent enforcement history shows how costly this can get. In early 2025, an FDA inspection of a major pharmaceutical company's pharmacovigilance system uncovered multiple high-severity failures, including two patient deaths associated with a marketed drug and a case that had to be invalidated because patient identifiers were missing. The FDA later escalated its findings into a formal warning letter after determining the company's corrective actions were insufficient. More broadly, compliance analysts have found that 60% to 80% of drug-related FDA warning letters cite data integrity issues as a primary or contributing factor. These are not abstract risks. They translate into inspection findings, corrective action plans, and in serious cases, restrictions on how a product can stay on the market.
None of this means pharmacovigilance teams are doing a bad job. It means the traditional model of quality control, built around manual review of steadily increasing case volumes, is reaching its limits. This is where artificial intelligence, and specifically natural language processing, is starting to make a measurable difference. Industry reporting suggests AI-assisted case processing can automate a meaningful share of the routine work in ICSR handling, with some organizations reporting reductions in processing time of 60% to 70% while maintaining accuracy in medical information extraction. The value is not in replacing judgment. It is in clearing away the repetitive work that keeps qualified people from using their judgment where it matters most.
The first and most obvious application is validating whether a case meets the four minimum elements before it ever reaches a human reviewer. AI models trained on structured intake data and free-text narratives can flag missing patient identifiers, absent reporter details, or unclear drug names within seconds of intake, rather than waiting for a manual reviewer to catch the gap hours or days later. This front-loads quality control to the earliest possible point in the case lifecycle, which is exactly where regulators expect it to happen.
Beyond checking for missing fields, AI can compare information across different parts of the same case. If a narrative describes a patient as hospitalized but the seriousness field says "non-serious," a well-trained model can catch that mismatch automatically. This kind of cross-field consistency checking is difficult to scale manually, especially across large volumes, but it is exactly the kind of pattern-matching task that natural language processing tools handle well. NLP-based extraction from unstructured medical text has already shown strong performance in research settings, with adverse drug reaction detection models achieving F-measures in the 0.72 to 0.82 range depending on the data source.
Some pharmacovigilance platforms are beginning to apply a quality score to each case as it moves through the workflow, similar in spirit to the structured scoring framework used in the Eudravigilance study mentioned earlier. A score gives reviewers a fast way to triage their workload, focusing extra attention on cases that scored poorly on completeness or consistency rather than treating every case the same way. Over time, this scoring data can also reveal patterns, such as a particular reporting source or region that consistently produces lower-quality cases, information that can guide targeted training or process fixes.
Perhaps the most immediately useful AI application is automated detection of what is missing from a case, paired with a suggested, specific follow-up question. Instead of a generic request for "more information," an AI system can identify that the onset date is missing and generate a targeted query asking the reporter for exactly that detail. Faster, more specific follow-up requests tend to get better response rates, which shortens the time a case sits incomplete in the queue.
None of the above should be read as a case for full automation. Pharmacovigilance is a discipline built on clinical judgment, and AI tools work best when they support that judgment rather than replace it. As of 2025, no pharmacovigilance-specific AI regulation exists in most major markets; instead, general Good Pharmacovigilance Practice standards apply, which means any AI system used in this context must be validated, documented, and shown to be fit for purpose. That validation requirement exists precisely because AI outputs are not treated as a substitute for a qualified medical assessment.
There is an important distinction between AI that assists a reviewer and AI that makes a decision on its own. Flagging a missing field, scoring a case for completeness, or suggesting a follow-up question are all assistive functions. They speed up the process without making a clinical call. Determining causality, seriousness, or whether a case represents a genuine safety signal is a different category of task entirely, one that still requires a trained medical professional to interpret context, weigh confounding factors, and apply clinical reasoning that current AI models are not equipped to replicate reliably.
This is why physician or medically qualified sign-off remains a non-negotiable step in any defensible pharmacovigilance process, AI-assisted or not. Industry surveys suggest that safety staff largely see AI as a productivity aid rather than a threat to their role: in one survey, more than 80% of safety professionals said AI tools improved their productivity, and about 60% said the tools reduced their day-to-day stress. That framing, AI handling the repetitive groundwork so people can focus on the decisions that require expertise, is the model most pharmacovigilance leaders are converging on.
Improving ICSR quality is not about buying a single tool and expecting the problem to disappear. It is about redesigning the workflow so that quality checks happen earlier, more consistently, and with better visibility into where problems tend to occur. A defensible process combines three things: automated validation at intake to catch the obvious gaps immediately, consistency and quality scoring to help reviewers prioritize their time, and a clear, documented boundary between what AI is allowed to do and what still requires a qualified human sign-off.
Pharmacovigilance teams that get this balance right are not just reducing rework or avoiding audit findings, though both of those benefits are real and measurable. They are building a system that can hold up under regulatory scrutiny because every step, automated or manual, has a clear rationale behind it. In an environment where data volumes keep growing and reporting timelines keep tightening, that combination of speed and defensibility is what separates a pharmacovigilance function that merely keeps pace from one that genuinely protects patients.
Book a walkthrough of Zen Case AI and Zen Protocol AI, or subscribe to get new articles as we publish them.